Spatial modeling of HIV cryptic viremia and 2-LTR formation during raltegravir intensification

Journal of Theoretical Biology

Volumn 345, Issue , 2014, Pages 61-69

  Cardozo, E Fabian ^a   Luo, Rutao ^a   Piovoso, Michael J ^b   Zurakowski, Ryan ^a  

^a UNIVERSITY OF DELAWARE   (United States)

^b PENNSYLVANIA STATE UNIVERSITY   (United States)

Author keywords

Cryptic viremia; Drug sanctuary; HIV; Mathematical biology

Indexed keywords

RALTEGRAVIR;

EXPERIMENTAL STUDY; HUMAN IMMUNODEFICIENCY VIRUS; MONTE CARLO ANALYSIS; NUMERICAL MODEL; SPATIAL ANALYSIS;

ARTICLE; BASIC REPRODUCTION NUMBER; COMPARTMENT MODEL; DIFFUSION; EXPERIMENTAL DESIGN; HUMAN IMMUNODEFICIENCY VIRUS; LIMIT OF DETECTION; LONG TERMINAL REPEAT; LYMPH FOLLICLE; MONTE CARLO METHOD; PRIORITY JOURNAL; REACTION ANALYSIS; VIREMIA; VIRUS LOAD; VIRUS REPLICATION;

CRYPTIC VIREMIA; DRUG SANCTUARY; HIV; MATHEMATICAL BIOLOGY;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; HIV INFECTIONS; HIV LONG TERMINAL REPEAT; HIV-1; HUMANS; LYMPH NODES; MODELS, BIOLOGICAL; MONTE CARLO METHOD; PYRROLIDINONES; VIRAL LOAD; VIREMIA; VIRUS REPLICATION;

EID: 84891933529     PISSN: 00225193     EISSN: 10958541     Source Type: Journal    
DOI: 10.1016/j.jtbi.2013.12.020     Document Type: Article

References (55)

1. Anderson J.A., Archin N.M., Ince W., Parker D., Wiegand A., Coffin J.M., Kuruc J., Eron J., Swanstrom R., Margolis D.M. Clonal sequences recovered from plasma from patients with residual HIV-1 viremia and on intensified antiretroviral therapy are identical to replicating viral RNAs recovered from circulating resting CD4+ T cells. J. Virol. 2011, 85(10):5220-5223.
2. Baldazzi V., Paci P., Bernaschi M., Castiglione F. Modeling lymphocyte homing and encounters in lymph nodes. BMC Bioinform. 2009, 10:387.
3. Bazzoli C., Jullien V., Le Tiec C., Rey E., Mentré F., Taburet A.-M. Intracellular pharmacokinetics of antiretroviral drugs in HIV-infected patients, and their correlation with drug action. Clin. Pharmacokinet. 2010, 49(1):17-45.
4. Beltman J.B., Marée A.F.M., Lynch J.N., Miller M.J., De Boer R.J. Lymph node topology dictates T cell migration behavior. J. Exp. Med. 2007, 204(4):771-780.
5. Bielecki A., Kalita P. Model of neurotransmitter fast transport in axon terminal of presynaptic neuron. J. Math. Biol. 2008, 56(4):559-576.
6. Bielecki A., Kalita P., Lewandowski M., Skomorowski M. Compartment model of neuropeptide synaptic transport with impulse control. Biol. Cybern. 2008, 99(6):443-458.
7. Buzón M.J., Massanella M., Llibre J.M., Esteve A., Dahl V., Puertas M.C., Gatell J.M., Domingo P., Paredes R., Sharkey M., Palmer S., Stevenson M., Clotet B., Blanco J., Martinez-Picado J. HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects. Nat. Med. 2010, 16(4):460-465.
8. Callaway D.S., Perelson A.S. HIV-1 infection and low steady state viral loads. Bull. Math. Biol. 2002, 64(1):29-64.
9. Cardozo, E.F., Vargas, C.A., Zurakowski, R., 2012. A compartment based model for the formation of 2-LTR circles after raltegravir intensification. In: 51st IEEE Conference on Decision and Control, Maui, HI, pp. 4924-4929.
10. Chun T.W., Stuyver L., Mizell S.B., Ehler L.A., Mican J.A., Baseler M., Lloyd A.L., Nowak M.A., Fauci A.S. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc. Natl. Acad. Sci. U. S. A. 1997, 94(24):13193-13197.
11. Chun T.W., Davey R.T., Ostrowski M., Shawn Justement J., Engel D., Mullins J.I., Fauci A.S. Relationship between pre-existing viral reservoirs and the re-emergence of plasma viremia after discontinuation of highly active anti-retroviral therapy. Nat. Med. 2000, 6(7):757-761.
12. Crosley L.K., Duthie S.J., Polley A.C., Bouwman F.G., Heim C., Mulholland F., Horgan G., Johnson I.T., Mariman E.C., Elliott R.M., Daniel H., de Roos B. Variation in protein levels obtained from human blood cells and biofluids for platelet, peripheral blood mononuclear cell, plasma, urine and saliva proteomics. Genes Nutr. 2009, 4(2):95-102.
13. Dahl V., Josefsson L., Palmer S. HIV reservoirs, latency, and reactivation. prospects for eradication. Antiviral Res. 2010, 85(1):286-294.
14. Dornadula G., Zhang H., VanUitert B., Stern J., Livornese L., Ingerman M.J., Witek J., Kedanis R.J., Natkin J., DeSimone J., Pomerantz R.J. Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy. J. Am. Med. Assoc. 1999, 282(17):1627-1632.
15. Dreij K., Chaudhry Q.A., Jernström B., Morgenstern R., Hanke M. A method for efficient calculation of diffusion and reactions of lipophilic compounds in complex cell geometry. PLoS ONE 2011, 6(8):e23128. 10.1371/journal.pone.0023128.
16. Evering T.H., Mehandru S., Racz P., Tenner-Racz K., Poles M.A., Figueroa A., Mohri H., Markowitz M. Absence of HIV-1 evolution in the gut-associated lymphoid tissue from patients on combination antiviral therapy initiated during primary infection. PLoS Pathog. 2012, 8(2):e1002506.
17. Finzi D., Hermankova M., Pierson T., Carruth L.M., Buck C., Chaisson R.E., Quinn T.C., Chadwick K., Margolick J., Brookmeyer R., Gallant J., Markowitz M., Ho D.D., Richman D.D., Siliciano R.F. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 1997, 278(5341):1295-1300.
18. Folkvord J.M., Armon C., Connick E. Lymphoid follicles are sites of heightened human immunodeficiency virus type 1 replication and reduced antiretroviral effector mechanisms. AIDS Res. Hum. Retrovir. 2005, 21(5):363-370.
19. Frost S., Martinez-Picado J., Ruiz L., Clotet B., Brown A. Viral dynamics during structured treatment interruptions of chronic human immunodeficiency virus type 1 infection. J. Virol. 2002, 76(3):968-979.
20. Gandhi, R.T., Zheng, L., Bosch, R.J., Chan, E.S., Margolis, D.M., Read, S., Kallungal, B., Palmer, S., Medvik, K., Lederman, M.M., Alatrakchi, N., Jacobson, J.M., Wiegand, A., Kearney, M., Coffin, J.M., Mellors, J.W., Eron, J.J., AIDS Clinical Trials Group A5244 team, 2010. The effect of raltegravir ntensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trial. PLoS Med. 7 (8).
21. Gandhi R.T., Coombs R.W., Chan E.S., Bosch R.J., Zheng L., Margolis D.M., Read S., Kallungal B., Chang M., Goecker E.A., Wiegand A., Kearney M., Jacobson J.M., D'Aquila R., Lederman M.M., Mellors J.W., Eron J.J., AIDS Clinical Trials Group A5244 Team No effect of raltegravir intensification on viral replication markers in the blood of HIV-1-infected patients receiving antiretroviral therapy. J. Acquir. Immune Defic. Syndr. 2012, 59(3):229-235.
22. Girard J.-P., Moussion C., Förster R. HEVs, lymphatics and homeostatic immune cell trafficking in lymph nodes. Nat. Rev. Immunol. 2012, 12(11):762-773.
23. Ho D.D., Neumann A.U., Perelson A.S., Chen W., Leonard J.M., Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995, 373(6510):123-126.
24. Horiike M., Iwami S., Kodama M., Sato A., Watanabe Y., Yasui M., Ishida Y., Kobayashi T., Miura T., Igarashi T. Lymph nodes harbor viral reservoirs that cause rebound of plasma viremia in SIV-infected macaques upon cessation of combined antiretroviral therapy. Virology 2012, 423(2):107-118.
25. Kirschner D., Webb G.F., Cloyd M. Model of HIV-1 disease progression based on virus-induced lymph node homing and homing-induced apoptosis of CD4+ lymphocytes. J. Acquir. Immune Defic. Syndr. 2000, 24(4):352-362.
26. Kraehenbuhl J.P. The gut-associated lymphoid tissue. a major site of HIV replication and CD4 cell loss. Trends Microbiol. 1998, 6(11):419-420. (discussion 420-1).
27. Lafeuillade A., Khiri H., Chadapaud S., Hittinger G., Halfon P. Persistence of HIV-1 resistance in lymph node mononuclear cell RNA despite effective HAART. AIDS 2001, 15(15):1965-1969.
28. Lai B.E., Henderson M.H., Peters J.J., Walmer D.K., Katz D.F. Transport theory for HIV diffusion through in vivo distributions of topical microbicide gels. Biophys. J. 2009, 97(9):2379-2387.
29. Luo R., Piovoso M.J., Martinez-Picado J., Zurakowski R. HIV model parameter estimates from interruption trial data including drug efficacy and reservoir dynamics. PLoS ONE 2012, 7(7):e40198.
30. Luo R., Cardozo E.F., Piovoso M.J., Wu H., Buzón M.J., Martinez-Picado J., Zurakowski R. Modelling HIV-1 2-LTR dynamics following raltegravir intensification. J. R. Soc. Interface 2013, 10(84):20130186.
31. Marinho E.B.S., Bacelar F.S., Andrade R.F.S. A model of partial differential equations for HIV propagation in lymph nodes. Phys. A. Stat. Mech. Appl. 2012, 391(1-2):132-141.
32. Michaels S.H., Clark R., Kissinger P. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N. Engl. J. Med. 1998, 339(6):405-406.
33. Mirsky H.P., Miller M.J., Linderman J.J., Kirschner D.E. Systems biology approaches for understanding cellular mechanisms of immunity in lymph nodes during infection. J. Theor. Biol. 2011, 287:160-170.
34. Mueller S.N., Gebhardt T., Carbone F.R., Heath W.R. Memory T cell subsets, migration patterns, and tissue residence. Annu. Rev. Immunol. 2013, 31:137-161.
35. Murooka T.T., Deruaz M., Marangoni F., Vrbanac V.D., Seung E., von Andrian U.H., Tager A.M., Luster A.D., Mempel T.R. HIV-infected T cells are migratory vehicles for viral dissemination. Nature 2012, 490(7419):283-287.
36. Murray A.G., Jackson G.A. Viral dynamics. a model of the effects of size, shape, motion and abundance of single-celled planktonic organisms and other particles. Mar. Ecol. Prog. Ser. 1992, 89:103-116.
37. Nowak M., May R. Virus Dynamics. Mathematical Principles of Immunology and Virology 2000, Oxford University Press, New York.
38. Orenstein J.M., Feinberg M., Yoder C., Schrager L., Mican J.M., Schwartzentruber D.J., Davey R.T., Walker R.E., Falloon J., Kovacs J.A., Miller K.D., Fox C., Metcalf J.A., Masur H., Polis M.A. Lymph node architecture preceding and following 6 months of potent antiviral therapy. follicular hyperplasia persists in parallel with p24 antigen restoration after involution and CD4 cell depletion in an AIDS patient. AIDS 1999, 13(16):2219-2229.
39. Pantaleo G., Graziosi C., Butini L., Pizzo P.A., Schnittman S.M., Kotler D.P., Fauci A.S. Lymphoid organs function as major reservoirs for human immunodeficiency virus. Proc. Natl. Acad. Sci. U. S. A. 1991, 88(21):9838-9842.
40. Perelson A.S., Ribeiro R.M. Modeling the within-host dynamics of HIV infection. BMC Biol. 2013, 11(1):96.
41. Perelson A.S., Wiegel F.W. Scaling aspects of lymphocyte trafficking. J. Theor. Biol. 2009, 257(1):9-16.
42. Perelson A., Essunger P., Ho D. Dynamics of HIV-1 and CD4+ lymphocytes in vivo. AIDS 1997, 11(Suppl. A):S17-S24.
43. Popovic M., Tenner-Racz K., Pelser C., Stellbrink H.-J., van Lunzen J., Lewis G., Kalyanaraman V.S., Gallo R.C., Racz P. Persistence of HIV-1 structural proteins and glycoproteins in lymph nodes of patients under highly active antiretroviral therapy. Proc. Natl. Acad. Sci. U. S. A. 2005, 102(41):14807-14812.
44. Reigadas S., Andréola M.-L., Wittkop L., Cosnefroy O., Anies G., Recordon-Pinson P., Thiébaut R., Masquelier B., Fleury H. Evolution of 2-long terminal repeat episomal HIV-1 DNA in raltegravir-treated patients and in in vitro infected cells. J. Antimicrob. Chemother. 2010, 65(3):434-437.
45. Rong L., Perelson A.S. Modeling latently infected cell activation. viral and latent reservoir persistence, and viral blips in HIV-infected patients on potent therapy. PLoS Comput. Biol. 2009, 5(10):e1000533.
46. Sharkey M., Triques K., Kuritzkes D.R., Stevenson M. In vivo evidence for instability of episomal human immunodeficiency virus type 1 cDNA. J. Virol. 2005, 79(8):5203-5210.
47. Sharkey M., Babic D.Z., Greenough T., Gulick R., Kuritzkes D.R., Stevenson M. Episomal viral cDNAs identify a reservoir that fuels viral rebound after treatment interruption and that contributes to treatment failure. PLoS Pathog. 2011, 7(2):e1001303.
48. Sloan R.D., Wainberg M.A. The role of unintegrated DNA in HIV infection. Retrovirology 2011, 8:52.
49. Swartz M.A. The physiology of the lymphatic system. Adv. Drug Deliv. Rev. 2001, 50(1-2):3-20.
50. Thompson M.A., Aberg J.A., Hoy J.F., Telenti A., Benson C., Cahn P., Eron J.J., Günthard H.F., Hammer S.M., Reiss P., Richman D.D., Rizzardini G., Thomas D.L., Jacobsen D.M., Volberding P.A. Antiretroviral treatment of adult HIV infection. 2012 recommendations of the International Antiviral Society-USA panel. J. Am. Med. Assoc. 2012, 308(4):387-402.
51. Voltersvik P., Bostad L., Dyrhol-Riise A.M., Eide G.E., Røsok B.I., Olofsson J., Asjö B. Cystatin A and HIV-1 p24 antigen expression in tonsillar lymphoid follicles during HIV-1 infection and during highly active antiretroviral therapy. J. Acquir. Immune Defic. Syndr. 2006, 41(3):277-284.
52. von Andrian U.H., Mempel T.R. Homing and cellular traffic in lymph nodes. Nat. Rev. Immunol. 2003, 3(11):867-878.
53. Wei X., Ghosh S.K., Taylor M.E., Johnson V.A., Emini E.A., Deutsch P., Lifson J.D., Bonhoeffer S., Nowak M.A., Hahn B.H. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995, 373(6510):117-122.
54. Wong J.K., Hezareh M., Günthard H.F., Havlir D.V., Ignacio C.C., Spina C.A., Richman D.D. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 1997, 278(5341):1291-1295.
55. Zhu W., Jiao Y., Lei R., Hua W., Wang R., Ji Y., Liu Z., Wei F., Zhang T., Shi X., Wu H., Zhang L. Rapid turnover of 2-LTR HIV-1 DNA during early stage of highly active antiretroviral therapy. PLoS ONE 2011, 6(6):e21081.